PC8 is a selective dual inhibitor of PARP1/CDK6, with an IC50 of 0.126 µM for PARP1 and 0.197 µM for CDK6. PC8 does not alter PARP1 expression, but reduces the expression of its downstream target PAR. PC8 inhibits the canonical Wnt/beta-catenin signaling pathway. PC8 induces intracellular ROS accumulation and exacerbates DNA damage. PC8 inhibits the proliferation of triple-negative breast cancer (TNBC) cells. PC8 can be used for the research of triple-negative breast cancer[1].
Molecular Weight:
578.50
Formula:
C28H32BrN7O2
Target:
CDK,DNA/RNA Synthesis,PARP,Protease Activated Receptor (PAR),Reactive Oxygen Species (ROS),Wnt,beta-catenin
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
